Author

M. T. Barrett

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

A. T. Baker· 3 shared B. M. Nagalo· 3 shared Y. Zhou· 3 shared B. Jacobs· 2 shared C. Dumbauld· 2 shared J. M. Bogenberger· 2 shared K. Buetow· 2 shared M. Arora· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. T. Baker

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A platform for dissecting force sensitivity and multivalency in actin networks

J. T. Levin, A. Pan, M. T. Barrett, G. M. Alushin

This paper develops an in vitro platform to study how mechanical forces affect actin-binding protein interactions in multi-filament networks, revealing that force enhances -catenin binding to small filament bundles.

bioRxiv · Aug 15, 2023 · PreprintBiophysics

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers

B. M. Nagalo, Y. Zhou, E. L. Loeuillard, C. Dumbauld, O. Barro, N. Elliott, A. T. Baker, M. Arora, J. M. Bogenberger, N. Meurice, J. Petit, P. L. S. Uson Junior, F. Aslam, J. C. Chamcheu, C. C. Simoes, , M. Borad

This study characterizes Morreton virus (MORV) as a safe and effective oncolytic virotherapy for liver cancers, showing tumor regression in animal models with lower doses than VSV.

Hepatology · Jun 1, 2023Peer-reviewedImmunology

Multi-modal Efficacy of a Chimeric Vesiculovirus Expressing the Morreton Glycoprotein in Sarcoma

C. Dumbauld, O. Barro, N. M. Elliott, Y. Zhou, M. Gabere, E. Raupach, A. T. Baker, M. T. Barrett, K. Buetow, B. Jacobs, M. Seetharam, M. Borad, B. M. Nagalo

This study develops a chimeric vesiculovirus (VMG) expressing MorV glycoprotein, showing anti-tumor effects in sarcoma models with in vitro efficacy and in vivo tumor reduction.

bioRxiv · Sep 18, 2022 · PreprintImmunology

Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

M. Arora, J. M. Bogenberger, A. M. Abdelrahman, J. Yonkus, R. Alva-Ruiz, J. L. Leiting, X. Chen, P. L. Serrano Uson, C. R. Dumbauld, A. T. Baker, S. I. Gamb, J. B. Egan, Y. Zhou, B. M. Nagalo, N. Meurice, , M. J. Borad

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.

bioRxiv · Oct 26, 2020Cancer Biology